Canada Markets closed

Zymeworks Inc. (ZYME.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
33.10+0.53 (+1.63%)
At close: 02:58PM EST

Zymeworks Inc.

1385 West 8th Avenue
Suite 540
Vancouver, BC V6H 3V9
604 678 1388

Full Time Employees455

Key Executives

NameTitlePayExercisedYear Born
Dr. Ali TehraniCo-Founder, Pres, CEO & Director877.66kN/A1972
Mr. Neil A. Klompas C.A., CPA, CPA, CAExec. VP of Bus. Operations & CFO589.86kN/A1972
Dr. Anthony J. Polverino Ph.D.Chief Scientific Officer & Exec. VP of Early Devel.606.71kN/A1963
Ms. Kathryn O'DriscollChief People Officer497.22kN/A1964
Mr. Daniel DexVP of Legal & Corp. Sec.N/AN/AN/A
Dr. Neil Josephson M.D.Chief Medical OfficerN/AN/AN/A
Mr. James Daniel Guylain PriourChief Commercial OfficerN/AN/A1967
Dr. David Poon Ph.D.VP of Bus. Devel. and Alliance ManagementN/AN/AN/A
Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D.VP of Intellectual PropertyN/AN/A1950
Ms. Wajida LeclercVP of HRN/AN/A1960
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Corporate Governance

Zymeworks Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.